VICTOR RIVERA to Maximum Tolerated Dose
This is a "connection" page, showing publications VICTOR RIVERA has written about Maximum Tolerated Dose.
Connection Strength
0.099
-
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma. Ann Oncol. 2013 Apr; 24(4):1104-11.
Score: 0.023
-
Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012 Apr; 69(4):849-60.
Score: 0.021
-
Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol. 2010 Oct 20; 28(30):4554-61.
Score: 0.020
-
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann Oncol. 2010 Jun; 21(6):1315-1322.
Score: 0.019
-
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008 Jan 20; 26(3):361-7.
Score: 0.016